Pre-, post-, and remote conditioning of the myocardium are well described adaptive
responses that markedly enhance the ability of the heart to withstand a prolonged …

Preconditioning, postconditioning, and remote conditioning of the myocardium enhance the
ability of the heart to withstand a prolonged ischemia/reperfusion insult and the potential to …

Repaglinide (RPG) is a short-acting insulin secretagogue widely prescribed for the treatment
of type 2 diabetes. It boosts insulin secretion by inhibiting the pancreatic ATP-sensitive …

Myocardial ischemia is considered the cornerstone of the treatment of patients with coronary
artery disease (CAD). Although the deleterious effects of myocardial infarction, the maximum …

Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are oral incretin-based glucose-
lowering agents with proven efficacy and safety in the management of type 2 diabetes …

The dipeptidyl peptidase-4 inhibitor vildagliptin (Galvus®) is approved for use as
monotherapy and combination therapy in type 2 diabetes mellitus. A fixed-dose combination …

The increasing burden of type 2 diabetes (T2D), in relation to alarming rise in the
prevalence; challenges in the diagnosis, prevention, and treatment; as well as the …

The prevalence of type 2 diabetes mellitus (T2DM) among elderly people is increasing.
Often associated with disabilities/comorbidities, T2DM lowers the chances of successful …

Cardiovascular disease, predominantly ischemic heart disease (IHD), is the leading cause
of death in diabetes mellitus (DM). In addition to eliciting cardiomyopathy, DM induces a …

Clinical observations are highly inconsistent with the use of the antidiabetic rosiglitazone
regarding its associated increased risk of myocardial infarction. This may be due to its …